Clinical effects of natalizumab on multiple sclerosis appear early in treatment course

Journal of Neurology

Volumn 260, Issue 5, 2013, Pages 1388-1395

  Kappos, Ludwig ^a   O'Connor, Paul W ^b   Polman, Christopher H ^c   Vermersch, Patrick ^d   Wiendl, Heinz ^e   Pace, Amy ^f   Zhang, Annie ^f   Hotermans, Christophe ^f  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIV LILLE   (France)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f BIOGEN   (United States)

Author keywords

Annualized relapse rate; Disease activity; Disease modifying therapy; Multiple sclerosis; Natalizumab; Relapse

Indexed keywords

BETA INTERFERON; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; NATALIZUMAB;

CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMMUNOLOGY; INTERNATIONAL COOPERATION; LONGITUDINAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; TIME; TREATMENT OUTCOME; ARTICLE; CONTROLLED CLINICAL TRIAL; RECURRENT DISEASE;

ANTIBODIES, MONOCLONAL, HUMANIZED; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; INTERNATIONAL COOPERATION; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME; RECURRENCE;

EID: 84885754913     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6809-7     Document Type: Article

References (38)

1. Caon C (2009) Maximising therapeutic outcomes in patients failing on current therapy. J Neurol Sci 277(Suppl 1):S33-S36.
2. Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, Weiner H, Weinstock-Guttman B, Khan O, Multiple Sclerosis Clinical Research Center DoNWSUSoM (2008) Intense immunosuppression in patients with rapidly worsening multiple sclerosis: Treatment guidelines for the clinician. Lancet Neurol 7(2):173-183.
3. Comi G (2009) Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clin Ther 31(6):1142-1157.
4. Coyle PK, Hartung HP (2002) Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- And frequency-dependent effects on clinical response. Mult Scler 8(1):2-9.
5. Tintore M (2008) Rationale for early intervention with immunomodulatory treatments. J Neurol 255(Suppl 1):37-43.
6. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338(5):278-285.
7. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4):655-661.
8. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, III, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39(3):285-294.
9. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45(7):1268-1276.
10. Kappos L, Radue EW, OConnor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387-401.
11. PRISMS (Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferonbeta-1a in relapsing/remitting multiple sclerosis. Lancet 352(9139):1498-1504.
12. Comi G, Filippi M, Wolinsky JS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49(3):290-297.
13. Kappos L, Antel J, Comi G, Montalban X, OConnor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355(11):1124-.
14. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, OConnor PW, International Natalizumab Multiple Sclerosis Trial Group (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348(1):15-23.
15. Polman CH, OConnor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, AFFIRM Investigators (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899-910.
16. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356(6364):63-66.
17. Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, OConnor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL Investigators (2009) The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 256(3):405-415.
18. Belachew S, Phan-Ba R, Bartholome E, Delvaux V, Hansen I, Calay P, Hafsi KE, Moonen G, Tshibanda L, Vokaer M (2011) Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 18(2):240-245.
19. Krysko KM, OConnor PW (2011) The Toronto observational study of natalizumab in multiple sclerosis. Can J Neurol Sci 38(3):422-428.
20. Outteryck O, Ongagna JC, Zephir H, Fleury MC, Lacour A, Blanc F, Vermersch P, de Seze, J (2010) Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol 257(2):207-211.
21. Putzki N, Yaldizli O, Maurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V (2010) Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 17(1):31-37.
22. Sangalli F, Moiola L, Bucello S, Annovazzi P, Rizzo A, Radaelli M, Vitello G, Grimaldi LM, Ghezzi A, Martinelli V, Comi G (2011) Efficacy and tolerability of natalizumab in relapsingremitting multiple sclerosis patients: A post-marketing observational study. Neurol Sci 31(Suppl 3):299-302.
23. Pellegrini F, Belachew S, Butzkueven H, Trojano M, Wiendl H, Zhang A, Hotermans C (2012) Long-term safety and efficacy of natalizumab and assessment of 2-year freedom from clinical disease activity in patients with multiple sclerosis in the TYSABRI Observational Programme. Presented at: 28th Congress of European Committee for Treatment & Research in Multiple Sclerosis, October 10-13, 2012. Lyon, France. P519. Mult Scler 18(4):220-221. P519.
24. Kappos L, Belachew S, Butzkueven H, Pellegrini F, Trojano M, Wiendl H, Zhang A, Hotermans C (2012) Long-term safety andefficacy and association between baseline treatment history and postbaseline relapses in multiple sclerosis patients treated with natalizumab in the TYSABRI Observational Program (TOP). Presented at: 64th Annual Meeting of the American Academy of Neurology, April 21-28, 2012. New Orleans. P04.133.
25. Nair VN (1984) Confidence bands for survival functions with censored data: A comparative study. Technometrics 26(3):265-275.
26. Fernandez O, Oreja-Guevara C, Arroyo R, Izquierdo G, Perez JL, Montalban X (2012) Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. J Neurol 259(9):1814-1823.
27. Holmen C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson T (2011) A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler 17(6):708-719.
28. Kallweit U, Jelcic I, Braun N, Fischer H, Zorner B, Schreiner B, Sokolov AA, Martin R, Weller M, Linnebank M (2012) Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort. Clin Neuropharmacol 35(2):77-80.
29. Lanzillo R, Bonavita S, Quarantelli M, Vacca G, Lus G, Amato L, Carotenuto A, Tedeschi G, Orefice G, Brescia M V (2012) Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. Neurol Sci. doi:10.1007/s10072-012-1088-8.
30. Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sorensen PS (2009) Efficacy of natalizumab in multiple sclerosis patients with high disease activity: A Danish nationwide study. Eur J Neurol 16(3):420-423.
31. Prosperini L, Borriello G, Fubelli F, Marinelli F, Pozzilli C (2011) Natalizumab treatment in multiple sclerosis: The experience of S. Andrea MS Centre in Rome. Neurol Sci 31 (Suppl 3): 303-307.
32. Putzki N, Yaldizli O, Buhler R, Schwegler G, Curtius D, Tettenborn B (2010) Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol 63(2):101-106.
33. Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, Aschenbach W, Pace A, Hyde R, Munschauer FE (2011) Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: Treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler 17(8):970-979.
34. Rudick RA, Sandrock A (2004) Natalizumab: Alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 4(4):571-580.
35. Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, Hughes RA, Palace J, Sharrack B, Swingler R, Young C, Moseley IF, MacManus DG, Donoghue S, Miller DH (1999) The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 53(3): 466-472.
36. Bayless KJ, Meininger GA, Scholtz JM, Davis GE (1998) Osteopontin is a ligand for the alpha4beta1 integrin. J Cell Sci 111(Pt 9):1165-1174.
37. Lobb RR, Hemler ME (1994) The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest 94(5):1722-1728.
38. Tchilian EZ, Owen JJ, Jenkinson EJ (1997) Anti-alpha 4 integrin antibody induces apoptosis in murine thymocytes and staphylococcal enterotoxin B-activated lymph node T cells. Immunology 92(3):321-327.